Minapharm Pharmaceuticals results, Q4 2021
Net profit, assets, equity and cash flow for Q4 2021, against the same period a year earlier, from the published financial statements.
Net profit114 millionEGP
Total assets4.11 billionEGP
Shareholders' equity1.94 billionEGP
Operating cash flow62.52 millionEGP
In short
- Minapharm Pharmaceuticals's net profit for Q4 2021 was about 114 million EGP.
- Total assets at the end of Q4 2021 were about 4.11 billion EGP, and shareholders' equity about 1.94 billion EGP.
- Operating cash flow for Q4 2021 was positive at 62.52 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit114 million——
Gross profit337 million——
Total assets4.11 billion——
Total liabilities2.16 billion——
Shareholders' equity1.94 billion——
Total liabilities and equity4.11 billion——
Operating cash flow62.52 million——
Investing cash flow-160 million——
Financing cash flow39.03 million——
Net change in cash-58.63 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy